News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Shaff Eric D.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/11/2023 |
4
| Shaff Eric D. (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
|
|
02/07/2023 |
4
| Shaff Eric D. (CEO and President) has filed a Form 4 on Seres Therapeutics, Inc.
Txns:
| Granted 125,000 restricted stock units
@ $0 Granted 250,000 options to buy
@ $5.5, valued at
$1.4M
|
|
07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/27/2022 |
4
| Shaff Eric D. (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.
Txns:
| Granted 8,888 options to buy
@ $0.7632, valued at
$6.8k
|
|
02/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/28/2021 |
4
| Shaff Eric D. (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.
Txns:
| Granted 8,888 options to buy
@ $9.97, valued at
$88.6k
|
|
02/08/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/03/2020 |
3
| Shaff Eric D. (Director) has filed a Form 3 on Sigilon Therapeutics, Inc. |
01/31/2020 |
4
| Shaff Eric D. (President CFO) has filed a Form 4 on Seres Therapeutics, Inc.
Txns:
| Granted 1,000,000 options to buy
@ $3.3, valued at
$3.3M
|
|
01/28/2020 |
4
| Shaff Eric D. (CEO and President) has filed a Form 4 on Seres Therapeutics, Inc.
Txns:
| Exercised 20,000 restricted stock units
@ $0 |
|
01/29/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/30/2018 |
4
| Shaff Eric D. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.
Txns:
| Sold 2,780 shares
@ $11.02, valued at
$30.6k
Exercised 8,000 restricted stock units
@ $0 Granted 120,000 options to buy
@ $10.42, valued at
$1.3M
|
|
01/27/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
06/30/2016 |
4
| Shaff Eric D. (CFO and EVP) has filed a Form 4 on Seres Therapeutics, Inc.
Txns:
| Sold 4,533 shares
@ $29.54, valued at
$133.9k
Exercised 4,533 options to buy
@ $7.79, valued at
$35.3k
|
|
06/29/2016 |
4
| Shaff Eric D. (CFO and EVP) has filed a Form 4 on Seres Therapeutics, Inc.
Txns:
| Sold 3,334 shares
@ $28, valued at
$93.4k
Sold 1,667 shares
@ $28.85, valued at
$48.1k
Exercised 3,334 options to buy
@ $7.79, valued at
$26k
Exercised 1,667 options to buy
@ $7.79, valued at
$13k
|
|
04/06/2016 |
4
| Shaff Eric D. (CFO and EVP) has filed a Form 4 on Seres Therapeutics, Inc.
Txns:
| Sold 6,568 shares
@ $28.85, valued at
$189.5k
Exercised 6,568 options to buy
@ $7.79, valued at
$51.2k
|
|
04/04/2016 |
4
| Shaff Eric D. (CFO and EVP) has filed a Form 4 on Seres Therapeutics, Inc.
Txns:
| Sold 1,095 shares
@ $25.13, valued at
$27.5k
Sold 6,568 shares
@ $26.5, valued at
$174.1k
Exercised 7,663 options to buy
@ $7.79, valued at
$59.7k
|
|
03/29/2016 |
4
| Shaff Eric D. (CFO and EVP) has filed a Form 4 on Seres Therapeutics, Inc.
Txns:
| Sold 5,473 shares
@ $24.07, valued at
$131.7k
Exercised 5,473 options to buy
@ $7.79, valued at
$42.6k
|
|
|
|